NASDAQ:CAPR

Founder-led company

stock price today

$7.66
-6.42
-45.6%
Financial Health
0
1
2
3
4
5
6
7
8
9

stock price monthly change

+220.00%
month

stock price quarterly change

+220.00%
quarter

stock price yearly change

+177.16%
year

key metrics

Market Cap
590.65M
Enterprise value
N/A
P/E
-3.64
EV/Sales
-4.35
EV/EBITDA
0.47
Price/Sales
0.06
Price/Book
N/A
PEG ratio
0.10
EPS
-0.87
Revenue
27.09M
EBITDA
-25.68M
Income
-24.31M
Revenue Q/Q
64.29%
Revenue Y/Y
389.52%
Profit margin
-938.23%
Oper. margin
-952.44%
Gross margin
0%
EBIT margin
-952.44%
EBITDA margin
-94.78%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

stock price history

stock forecast

financial statements

Average Price Target
Last Year

$31.6

Potential upside: 312.53%

Based on estimate of 4 analysts
  • Analysts Price target

  • Financials & Ratios estimates

(NASDAQ:CAPR): Profit margin
Jun 2023 3.91M -7.36M -188.04%
Sep 2023 6.18M -6.39M -103.31%
Dec 2023 12.08M -762.08K -6.3%
Mar 2024 4.90M -9.79M -199.6%
(NASDAQ:CAPR): Debt to assets
Jun 2023 46011198 43.28M 94.06%
Sep 2023 37152330 38.93M 104.81%
Dec 2023 58734327 36.13M 61.52%
Mar 2024 49444442 31.00M 62.72%
(NASDAQ:CAPR): Cash Flow
Jun 2023 -9.41M 6.46M 2.18M
Sep 2023 -8.79M 7.72M 221.08K
Dec 2023 -11.59M -5.86M 23.16M
Mar 2024 -1.26M -9.50M 2.29M

alternative data

(NASDAQ:CAPR): Employee count
Aug 2023 74
Sep 2023 74
Oct 2023 74
Nov 2023 74
Dec 2023 74
Jan 2024 74
Feb 2024 74
Mar 2024 101
Apr 2024 101
May 2024 101
Jun 2024 101
Jul 2024 101

other data

3.06% -8.14%
of CAPR is owned by hedge funds
751.02K -1.98M
shares is hold by hedge funds

(NASDAQ:CAPR): Insider trades (number of shares)
Period Buy Sel
Oct 2023 22993 0
Sep 2024 2798507 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
KRASNEY KAREN officer: EVP, GEN.. Common Stock 8,000 $1.39 $11,120
Option
KRASNEY KAREN officer: EVP, GEN.. Stock Option (Right to Buy) 5,000 $1.39 $6,950
Option
LITVACK FRANK director
Common Stock 20,391 $1.1 $22,430
Option
LITVACK FRANK director
Warrants (Right to Buy) 20,391 $1.1 $22,430
Purchase
NIPPON SHINYAKU CO LTD 10 percent owner
Common Stock, par value $0.001 per share 2,798,507 $5.36 $14,999,998
Option
MUSKET DAVID B director
Common Stock 34,000 $1.39 $47,260
Option
MUSKET DAVID B director
Stock Option (Right to Buy) 34,000 $1.39 $47,260
Option
COLLIER EARL M JR director
Common Stock 30,000 $1.39 $41,700
Option
COLLIER EARL M JR director
Stock Option (Right to Buy) 30,000 $1.39 $41,700
Option
MUSKET DAVID B director
Common Stock 16,156 $1.39 $22,457
Insider Compensation
Ms. Karen G. Krasney (1953) Executive Vice President, Gen. Counsel & Sec. $346,750
Mr. Anthony J. Bergmann M.B.A. (1986) Chief Financial Officer & Corporation Treasurer
$316,500
Dr. Linda Marbán (1963) Co-Founder, Pres, Chief Executive Officer & Director
$196,500
Dr. Frank Isaac Litvack FACC, M.D. (1956) Executive Chairman
$120,000
Saturday, 7 December 2024
seekingalpha.com
Friday, 6 December 2024
seekingalpha.com
Monday, 2 December 2024
globenewswire.com
Wednesday, 13 November 2024
seekingalpha.com
zacks.com
globenewswire.com
Monday, 11 November 2024
zacks.com
Thursday, 7 November 2024
zacks.com
Tuesday, 5 November 2024
zacks.com
Friday, 18 October 2024
globenewswire.com
Thursday, 17 October 2024
globenewswire.com
Wednesday, 16 October 2024
globenewswire.com
Friday, 11 October 2024
globenewswire.com
Wednesday, 9 October 2024
zacks.com
globenewswire.com
Tuesday, 8 October 2024
zacks.com
Friday, 4 October 2024
globenewswire.com
Tuesday, 1 October 2024
benzinga.com
Monday, 30 September 2024
marketbeat.com
Sunday, 29 September 2024
247wallst.com
Tuesday, 24 September 2024
seekingalpha.com
zacks.com
Monday, 23 September 2024
globenewswire.com
Tuesday, 17 September 2024
globenewswire.com
Friday, 6 September 2024
globenewswire.com
Thursday, 8 August 2024
seekingalpha.com
Wednesday, 7 August 2024
zacks.com
Tuesday, 25 June 2024
globenewswire.com
globenewswire.com
Monday, 17 June 2024
seekingalpha.com
  • What's the price of stock today?

    One share of  stock can currently be purchased for approximately $7.66.

  • When is 's next earnings date?

    Unfortunately, 's (CAPR) next earnings date is currently unknown.

  • Does pay dividends?

    No, does not pay dividends.

  • How much money does make?

    has a market capitalization of 590.65M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 887.79% to 25.18M US dollars.

  • What is 's stock symbol?

    null is traded on the NASDAQ under the ticker symbol "CAPR".

  • What is 's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of ?

    Shares of can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are 's key executives?

    's management team includes the following people:

    • Ms. Karen G. Krasney Executive Vice President, Gen. Counsel & Sec.(age: 72, pay: $346,750)
    • Mr. Anthony J. Bergmann M.B.A. Chief Financial Officer & Corporation Treasurer(age: 39, pay: $316,500)
    • Dr. Linda Marbán Co-Founder, Pres, Chief Executive Officer & Director(age: 62, pay: $196,500)
    • Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman(age: 69, pay: $120,000)
  • Is founder-led company?

    Yes, is a company led by its founder Dr. Linda Marbán.

  • How many employees does have?

    As Jul 2024, employs 101 workers.

  • When went public?

    null is publicly traded company for more then 18 years since IPO on 13 Feb 2007.

  • What is 's official website?

    The official website for is capricor.com.

  • Where are 's headquarters?

    is headquartered at 10865 Road to the Cure, San Diego, CA.

  • How can i contact ?

    's mailing address is 10865 Road to the Cure, San Diego, CA and company can be reached via phone at +31 3583200.

  • What is stock forecast & price target?

    Based on 4 Wall Street analysts` predicted price targets for in the last 12 months, the avarage price target is $31.6. The average price target represents a 312.53% change from the last price of $7.66.

company profile:

Exchange:

NASDAQ

Full time employees:

101

Industry:

Biotechnology

Sector:

Healthcare

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

10865 Road to the Cure
San Diego, CA 92121

CIK: 0001133869
ISIN: US14070B3096
CUSIP: 14070B309